pravastatin has been researched along with Disease Exacerbation in 80 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 21 (26.25) | 18.2507 |
| 2000's | 39 (48.75) | 29.6817 |
| 2010's | 19 (23.75) | 24.3611 |
| 2020's | 1 (1.25) | 2.80 |
| Authors | Studies |
|---|---|
| Andia, ME; Botnar, RM; Lavin Plaza, B; Lorrio, S; Phinikaridou, A; Potter, M; Rashid, I | 1 |
| Jeon, Y; Kim, S; Lee, JH; Min, JJ; Ryu, DK; Shin, BS; Shin, YH | 1 |
| Clifton, J; Lang, T; Neher, J; Safranek, S | 1 |
| Daida, H; Hata, M; Kaku, K; Kawamori, R; Kishimoto, J; Kurabayashi, M; Masuda, I; Nohara, R; Sakuma, I; Yamazaki, T; Yokoi, H; Yoshida, M | 3 |
| Lee, CW; Park, SJ | 1 |
| Chertow, GM; Erickson, KF; Garber, AM; Goldhaber-Fiebert, JD; Japa, S; Owens, DK | 1 |
| Barnes, EH; Blankenberg, S; Colquhoun, DM; Fournier, M; Nestel, PJ; Simes, J; Sullivan, DR; Tonkin, AM; White, HD | 1 |
| Cadnapaphornchai, MA | 1 |
| Bissler, JJ | 1 |
| Carter, D; Chandraker, A; Gabardi, S; Kim, M; Klasek, R; Mackenzie, MR; Ramasamy, S; Tan, CS | 1 |
| Brower, V | 1 |
| Brener, SJ; Hu, T; Ivanc, TB | 1 |
| Baimbridge, C; Barzilay, J; Basile, JN; Davis, BR; Henriquez, MA; Huml, A; Kopyt, N; Louis, GT; Pressel, SL; Rahman, M; Rosendorff, C; Sastrasinh, S; Stanford, C | 1 |
| Tonelli, M | 1 |
| Coombes, JS; Fairley, KF; Fassett, RG; Kincaid-Smith, P; Packham, D | 1 |
| de Vries, JP; Hoefer, IE; Hurks, R; Kerver, M; Moll, FL; Pasterkamp, G; Schoneveld, A; Tangelder, MJ; Vink, A | 1 |
| Strandberg, TE | 1 |
| Alipour, A; Cabezas, MC; Defesche, JC; Elte, JW; Jukema, JW; Ribalta, J; Vallvé, JC; Zwinderman, AH | 1 |
| Cadnapaphornchai, MA; George, DM; Masoumi, A; McFann, K; Schrier, RW; Strain, JD | 1 |
| Hirayama, A; Nagao, K; Tani, S | 1 |
| Fukui, K; Hibi, K; Kunishima, T; Michishita, I; Miyake, S; Morino, Y; Muramatsu, T; Nozato, T; Nozue, T; Onishi, Y; Sato, A; Takeyama, Y; Terashima, M; Tohyama, S; Umezawa, S; Yamamoto, S; Yamauchi, T | 1 |
| Shah, PK | 1 |
| Ako, JY; Daida, H; Eto, M; Kurata, T; Mokuno, H; Nishide, T; Ouchi, Y; Saito, Y; Sato, H; Tango, T; Yamada, N; Yamaguchi, H | 1 |
| Kerensky, RA; Monroe, VS; Pepine, CJ; Rivera, E; Smith, KM | 1 |
| Agema, WR; Boekholdt, SM; Jukema, JW; Kastelein, JJ; Peters, RJ; Reitsma, PH; van der Wall, EE; Zwinderman, AH | 1 |
| Hayashi, J; Kikuchi, K; Maeda, N; Okada, K; Sawayama, Y; Shimizu, C; Tatsukawa, M | 1 |
| Kröger, K; Wittlinger, T | 1 |
| Brodie, B; Brown, BG; Cooper, CJ; Crowe, T; DeMaria, AN; Ganz, P; Grines, CL; Howard, G; Nissen, SE; Schoenhagen, P; Tuzcu, EM; Vogel, RA | 1 |
| Agema, WR; Boer, JM; de Maat, MP; Feskens, EJ; Jukema, JW; Kastelein, JJ; Rabelink, TJ; van Boven, AJ; van der Wall, EE; Zwinderman, AH | 1 |
| Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG | 1 |
| Agema, WR; de Maat, MP; Kastelein, JJ; Rabelink, TJ; van der Wall, EE; Wouter Jukema, J; Zwinderman, AH | 1 |
| Baggio, G; Bond, MG; Crepaldi, G; Gallus, G; Magni, A; Mancia, G; Rubba, P; Sampieri, L; Sperti, G; Veglia, F; Ventura, A; Zanchetti, A | 1 |
| Kurachi, O; Maruo, T; Matsuo, H; Nakago, S; Oki, N; Takeuchi, K; Yamanaka, Y | 1 |
| Adams, GJ; Ballantyne, CM; Greene, J; Harrist, R; Insull, W; Karmonik, C; Kimball, KT; Morrisett, JD; Vick, GW | 1 |
| Crowe, T; Ganz, P; Magorien, RD; Nissen, SE; O'Shaughnessy, C; Orazem, J; Sasiela, WJ; Schoenhagen, P; Tsai, J; Tuzcu, EM | 1 |
| Blauw, GJ; Bollen, EL; de Craen, AJ; Ford, I; ten Dam, VH; van Buchem, MA; van den Heuvel, DM; Westendorp, RG | 1 |
| Daida, H; Endo, M; Furuse, A; Hosoda, S; Hosoda, Y; Makuuchi, H; Nakamura, H; Ohashi, Y; Watanabe, M; Yamaguchi, H; Yasui, H | 1 |
| Curhan, G; Jhangri, GS; Pfeffer, M; Sacks, F; Tonelli, M | 1 |
| Ichihara, G; Ichihara, S; Kawanishi, S; Nagata, K; Noda, A; Obata, K; Oikawa, S; Xu, J; Yamada, Y; Yokota, M | 1 |
| Admiraal-Behloul, F; Blauw, GJ; Bollen, EL; de Craen, AJ; Jolles, J; Murray, HM; Olofsen, H; ten Dam, VH; van Buchem, MA; van den Heuvel, DM; Westendorp, RG | 1 |
| Chen, MS; Crowe, T; Kapadia, S; Loyd, AB; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM | 1 |
| Hazen, SL; Nicholls, SJ; Nissen, SE; Ntanios, F; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wun, CC | 1 |
| Bardou, M; Dumas, M; Goirand, F; Guerard, P; Lirussi, F; Rakotoniaina, Z; Rochette, L | 1 |
| Furusyo, N; Hayashi, J; Maeda, S; Ohnishi, H; Okada, K; Sawayama, Y | 1 |
| Watson, KE | 1 |
| Rouhiainen, H; Rouhiainen, P; Salonen, JT | 1 |
| Bruin, T; Bruschke, AV; Gagné, E; Groenemeijer, B; Hayden, MR; Henneman, JA; Jansen, H; Jukema, JW; Kastelein, JJ; Molhoek, GP; Reiber, JH; van Boven, AJ; Zwinderman, AH | 1 |
| Bianchi, G; Bond, MG; Crepaldi, G; D'Alò, G; Descovich, G; Feruglio, FS; Gallus, G; Mancini, M; Mercuri, M; Ricci, G; Rubba, P; Sirtori, CR; Veglia, F; Ventura, A | 1 |
| Angelin, B; Juliusson, G; Vitols, S | 1 |
| Mikuriya, Y; Nasu, M; Tamura, A | 1 |
| Akasaka, T; Hozumi, T; Morioka, S; Takagi, T; Yoshida, K; Yoshikawa, J | 1 |
| Bassand, JP; Bertrand, ME; Cassagnes, J; Castaigne, A; Commeau, P; Danchin, N; Fruchart, JC; Grollier, G; Lablanche, JM; Machecourt, J; McFadden, EP; Mossard, JM; Vacheron, A; Van Belle, E | 1 |
| Bruschke, AV; Cobbaert, C; Jukema, JW; Lindemans, J; Withagen, AJ; Zwinderman, AH | 1 |
| Bruschke, AV; de Knijff, P; Jukema, JW; Kastelein, JJ; Kuivenhoven, JA; Lie, KI; McPherson, R; Zwinderman, AH | 1 |
| Chia, D; Hirata, M; Katznelson, S; Kobashigawa, JA; Ozawa, M; Terasaki, PI; Wang, XM; Zhong, HP | 1 |
| Gamble, G; Hart, H; MacMahon, S; Scott, J; Sharpe, N; Simes, J; White, H | 1 |
| Goldstein, MR | 1 |
| Dullaart, RP; van Tol, A | 1 |
| Ackerstaff, RG; Bom, N; Bruschke, AV; de Groot, E; Jukema, JW; Lie, KI; Montauban van Swijndregt, AD; van der Steen, AF; Zwinderman, AH | 1 |
| Bruschke, AV; Jukema, JW; van Boven, AJ; Van der Laarse, A; Zwinderman, AH | 1 |
| Albarrán, OG; García-Robles, R; Rábano, A; Ruilope, LM; Villa, E | 1 |
| Pitt, B | 1 |
| Azuma, N; Matsugane, T; Motohashi, K; Nishide, T; Nobuto, T; Suzuki, M; Yamane, S | 1 |
| Braunwald, E; Davis, BR; Flaker, GC; Moyé, LA; Pfeffer, MA; Rouleau, JL; Sacks, FM; Warnica, JW; Webel, RR | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Pedersen, TR | 1 |
| Bandoh, T; Hayashi, S; Ishikawa, J; Kimura, M; Kusumi, Y; Mitani, H; Niihashi, M; Sakurai, I; Totsuka, T | 1 |
| Baldassarre, D; Bong, MG; Collatina, S; Crepaldi, G; Fisicaro, M; Gallus, G; Gobbi, C; Mancini, M; Ricci, G; Rimondi, S; Sirtori, CR; Veglia, F; Ventura, A | 1 |
| Brown, WV | 1 |
| Su, DH; Yeo, KT | 1 |
| Crisby, M; Nilsson, J; Nordin-Fredriksson, G; Shah, PK; Yano, J; Zhu, J | 1 |
| Baggio, G; Bond, MG; Collatina, S; Crepaldi, G; Gallus, GV; Mancia, G; Rubba, P; Sampieri, L; Serrotti, E; Veglia, F; Ventura, A; Zanchetti, A | 1 |
| Bachmann, GA; Callister, TQ; Davidson, M; Kafonek, S; Laskey, R; Pittman, D; Raggi, P; Scott, R; Welty, FK | 1 |
| Griffin, BP; Lauer, MS; Novaro, GM; Pearce, GL; Sprecher, DL; Tiong, IY | 1 |
| Bru, C; Campistol, JM; Cofan, F; Cofan, M; Gilabert, R; Nunez, I; Oppenheimer, F; Ros, E; Zambon, D | 1 |
| Freedman, DS; Otvos, JD; Rosenson, RS | 1 |
12 review(s) available for pravastatin and Disease Exacerbation
| Article | Year |
|---|---|
Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.
Topics: Aged; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Drug Costs; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Failure, Chronic; Male; Markov Chains; Myocardial Infarction; Pravastatin; Primary Prevention; Quality-Adjusted Life Years; Rhabdomyolysis; Risk; Sex Factors; Stroke; United States | 2013 |
Autosomal dominant polycystic kidney disease in children.
Topics: Blood Pressure; Child; Child, Preschool; Diet, Sodium-Restricted; Disease Progression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Polycystic Kidney, Autosomal Dominant; Pravastatin; Prognosis; Renal Dialysis; Ultrasonography | 2015 |
Therapies for polycystic kidney disease.
Topics: Diet, Sodium-Restricted; Directive Counseling; Disease Progression; Exercise; Fruit; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Polycystic Kidney Diseases; Pravastatin; Prognosis; Renin-Angiotensin System; Risk Reduction Behavior; Vegetables | 2015 |
Lipid-lowering drugs and heart failure: where do we go after the statin trials?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pravastatin; Primary Prevention; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Triglycerides | 2010 |
Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; C-Reactive Protein; Coronary Artery Disease; Coronary Thrombosis; Disease Progression; Endothelium, Vascular; Enoxaparin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Macrophages; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pravastatin; Randomized Controlled Trials as Topic; Secondary Prevention; Severity of Illness Index | 2003 |
[Role of lipid lowering therapy in patients with peripheral arterial occlusive disease].
Topics: Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Disease Progression; Exercise Test; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Jejunoileal Bypass; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2004 |
Rosuvastatin-induced arrest in progression of renal disease.
Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
What is the evidence in favor of low-dose statin therapy in 2008?
Topics: Cardiovascular Diseases; Disease Progression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Risk Assessment; Simvastatin; Treatment Outcome | 2008 |
Results of recent trials on the progression of coronary artery disease and recurrent ischemic events: implications for interventional cardiology.
Topics: alpha-Linolenic Acid; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diet Therapy; Disease Progression; Humans; Myocardial Ischemia; Pravastatin | 1994 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
Statin trials and goals of cholesterol-lowering therapy after AMI.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Europe; Humans; Myocardial Infarction; Myocardial Ischemia; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; United States | 1999 |
Cholesterol lowering in atherosclerosis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Simvastatin | 2000 |
45 trial(s) available for pravastatin and Disease Exacerbation
| Article | Year |
|---|---|
Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Japan; Lipid Metabolism; Male; Middle Aged; Outcome Assessment, Health Care; Pharmacovigilance; Pravastatin; Preventive Health Services; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease.
Topics: Aged; Angina, Unstable; Australia; Biomarkers; Coronary Disease; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Middle Aged; Myocardial Infarction; New Zealand; Pravastatin; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Up-Regulation | 2013 |
Change in carotid intima-media thickness in a high-risk group of patients by intensive lipid-lowering therapy with rosuvastatin: subanalysis of the JART study.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Anticholesteremic Agents; Cholesterol; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hypercholesterolemia; Hypertension; Incidence; Kidney Diseases; Kidney Failure, Chronic; Male; Middle Aged; Pravastatin; Treatment Outcome | 2008 |
Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease.
Topics: Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Pravastatin; Prospective Studies; Proteinuria | 2010 |
Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants.
Topics: Adolescent; Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Child; Disease Progression; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Kidney; Lisinopril; Male; Polycystic Kidney, Autosomal Dominant; Pravastatin; Renin-Angiotensin System; Young Adult | 2011 |
Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study.
Topics: Aged; Asian People; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Hypolipidemic Agents; Japan; Longitudinal Studies; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Single-Blind Method; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease.
Topics: Aged; Biomarkers; Chromatography, Gas; Coronary Artery Disease; Coronary Vessels; Disease Progression; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Prospective Studies; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Preventing angiographic progression of coronary atherosclerosis with pravastatin.
Topics: Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Disease Progression; Endpoint Determination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Regression Analysis; Risk Factors; Treatment Outcome | 2003 |
Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
Topics: Amino Acid Substitution; Cohort Studies; Coronary Artery Disease; Disease Progression; Disease-Free Survival; Drosophila Proteins; Gene Frequency; Genetic Carrier Screening; Genetic Predisposition to Disease; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Membrane Glycoproteins; Multicenter Studies as Topic; Polymorphism, Genetic; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Cell Surface; Risk Assessment; Toll-Like Receptor 4; Toll-Like Receptors; Treatment Outcome | 2003 |
Association of Chlamydia pneumoniae antibody with the cholesterol-lowering effect of statins.
Topics: Adult; Aged; Aged, 80 and over; Angiography; Antibodies, Bacterial; Blotting, Western; Carotid Artery Diseases; Chlamydophila Infections; Chlamydophila pneumoniae; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin A; Immunoglobulin G; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Probucol; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2003 |
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Male; Middle Aged; Observer Variation; Pravastatin; Pyrroles; Ultrasonography, Interventional | 2004 |
An integrated evaluation of endothelial constitutive nitric oxide synthase polymorphisms and coronary artery disease in men.
Topics: Anticholesteremic Agents; Case-Control Studies; Coronary Angiography; Coronary Disease; Disease Progression; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Pravastatin; Statistics, Nonparametric | 2004 |
Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis.
Topics: Coronary Artery Disease; Disease Progression; Drug Resistance; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharide Receptors; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Pravastatin; Promoter Regions, Genetic; Receptors, Immunologic | 2004 |
Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Carotid Stenosis; Disease Progression; Diuretics; Drug Therapy, Combination; Female; Fosinopril; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pravastatin; Sodium Chloride Symporter Inhibitors | 2004 |
Effects of combined estriol/pravastatin therapy on intima-media thickness of common carotid artery in hyperlipidemic postmenopausal women.
Topics: Arteriosclerosis; Carotid Artery, Common; Disease Progression; Drug Therapy, Combination; Estriol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Postmenopause; Pravastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging.
Topics: Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Observer Variation; Pilot Projects; Pravastatin; Pyrroles; Reproducibility of Results; Simvastatin | 2004 |
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Regression Analysis; Risk Factors; Secondary Prevention; Ultrasonography, Interventional | 2005 |
Effect of pravastatin on cerebral infarcts and white matter lesions.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Cerebral Infarction; Cholesterol, LDL; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Magnetic Resonance Imaging; Male; Nerve Fibers, Myelinated; Pravastatin; Prospective Studies; Telencephalon; Treatment Failure | 2005 |
Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery.
Topics: Aged; Coronary Artery Bypass; Coronary Artery Disease; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin | 2005 |
Biomarkers of inflammation and progression of chronic kidney disease.
Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Disease Progression; Etanercept; Female; Humans; Hyperlipidemias; Immunoglobulin G; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Myocardial Infarction; Pravastatin; Receptors, Tumor Necrosis Factor | 2005 |
Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a non-demented elderly population.
Topics: Aged; Aged, 80 and over; Cerebral Infarction; Cerebral Ventricles; Cognition Disorders; Dementia, Vascular; Disease Progression; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Longitudinal Studies; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Pravastatin; Prospective Studies; Reaction Time; Statistics as Topic | 2006 |
Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Severity of Illness Index; Treatment Outcome; Ultrasonography, Interventional | 2006 |
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Coronary Disease; Coronary Vessels; Disease Progression; Endosonography; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pravastatin; Pyrroles; Risk Factors | 2006 |
Both hepatitis C virus and Chlamydia pneumoniae infection are related to the progression of carotid atherosclerosis in patients undergoing lipid lowering therapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Carotid Artery Diseases; Chlamydophila Infections; Chlamydophila pneumoniae; Disease Progression; Female; Hepatitis C; Humans; Male; Middle Aged; Pravastatin; Probucol | 2006 |
Association between low plasma vitamin E concentration and progression of early cortical lens opacities.
Topics: Adult; Anticholesteremic Agents; Arteriosclerosis; Cataract; Chromatography, High Pressure Liquid; Disease Progression; Finland; Humans; Linear Models; Male; Middle Aged; Pravastatin; Risk Factors; Time Factors; Vitamin E | 1996 |
The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.
Topics: Amino Acid Sequence; Angioplasty, Balloon, Coronary; Cohort Studies; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Disease Progression; Double-Blind Method; Genes; Heterozygote; Humans; Lipids; Lipoprotein Lipase; Lipoproteins; Middle Aged; Mutation; Pravastatin | 1996 |
Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study.
Topics: Anticholesteremic Agents; Carotid Stenosis; Disease Progression; Double-Blind Method; Female; Humans; Hypercholesterolemia; Italy; Lipids; Male; Middle Aged; Pravastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 1996 |
Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans--in vitro and in vivo studies.
Topics: Adult; Aged; B-Lymphocytes; Cell Division; Cholesterol; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Leukemia, Lymphoid; Lipids; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Mitogens; Pravastatin; Simvastatin; Thymidine; Tumor Cells, Cultured | 1997 |
Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group.
Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pravastatin; Prospective Studies; Time Factors | 1997 |
Intravascular ultrasound analysis of reduction in progression of coronary narrowing by treatment with pravastatin.
Topics: Aged; Anticholesteremic Agents; Constriction, Pathologic; Coronary Artery Disease; Disease Progression; Humans; Male; Middle Aged; Pravastatin; Treatment Outcome; Ultrasonography, Interventional | 1997 |
Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Combined Modality Therapy; Coronary Angiography; Coronary Disease; Disease Progression; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prospective Studies; Recurrence; Treatment Outcome | 1997 |
Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS)
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Humans; Hypercholesterolemia; Lipoprotein(a); Male; Middle Aged; Multivariate Analysis; Pravastatin; Prospective Studies; Reference Values | 1997 |
The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
Topics: Anticholesteremic Agents; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Coronary Artery Disease; Disease Progression; Dose-Response Relationship, Drug; Glycoproteins; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Genetic; Pravastatin; Prospective Studies | 1998 |
The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro.
Topics: Adjuvants, Immunologic; Anticholesteremic Agents; Cells, Cultured; Cholesterol; Cholesterol, LDL; Coronary Disease; Cyclosporine; Disease Progression; Drug Synergism; Female; Graft Rejection; Graft Survival; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Incidence; Killer Cells, Natural; Male; Middle Aged; Pravastatin; T-Lymphocytes, Cytotoxic; Transplantation, Homologous | 1998 |
Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group.
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Arteriosclerosis; Carotid Artery, Common; Carotid Stenosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; New Zealand; Pravastatin; Risk Factors; Treatment Outcome; Triglycerides; Ultrasonography | 1998 |
B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS).
Topics: Anticholesteremic Agents; Carotid Arteries; Coronary Angiography; Coronary Artery Disease; Disease Progression; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic; Ultrasonography | 1998 |
Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis.
Topics: Anticholesteremic Agents; Calcium Channel Blockers; Coronary Artery Disease; Disease Progression; Drug Synergism; Drug Therapy, Combination; Follow-Up Studies; Humans; Pravastatin | 1998 |
Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators.
Topics: Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Secondary Prevention; Survival Analysis; Treatment Outcome | 1999 |
Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study.
Topics: Anticholesteremic Agents; Carotid Artery Diseases; Cholesterol, LDL; Disease Progression; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Lipids; Male; Middle Aged; Pravastatin; Tunica Intima; Tunica Media; Ultrasonography | 2000 |
Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization.
Topics: Aged; Apolipoprotein B-100; Apolipoproteins B; Carotid Arteries; Carotid Artery Diseases; Cell Adhesion Molecules; Cell Death; Cholesterol; Collagen; Disease Progression; Endarterectomy, Carotid; Female; Humans; In Situ Nick-End Labeling; Inflammation; Lipid Metabolism; Lipoproteins; Male; Matrix Metalloproteinase 2; Metalloendopeptidases; Middle Aged; NF-kappa B; Pravastatin; Prospective Studies; Sweden; Tissue Inhibitor of Metalloproteinases; Treatment Outcome | 2001 |
Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lo
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carotid Arteries; Cholesterol; Disease Progression; Drug Therapy, Combination; Female; Fosinopril; Heart Rate; Humans; Hypercholesterolemia; Hypertension; Italy; Male; Middle Aged; Pravastatin; Systole; Tunica Intima; Ultrasonography | 2001 |
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Postmenopause; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Reproducibility of Results; Safety; Tomography, X-Ray Computed | 2001 |
Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients.
Topics: Arteriosclerosis; Carotid Arteries; Carotid Stenosis; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Transplantation; Lipids; Male; Postoperative Complications; Pravastatin; Time Factors | 2002 |
Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Humans; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Pravastatin; Treatment Outcome | 2002 |
23 other study(ies) available for pravastatin and Disease Exacerbation
| Article | Year |
|---|---|
Sustained Focal Vascular Inflammation Accelerates Atherosclerosis in Remote Arteries.
Topics: Animals; Anti-Inflammatory Agents; Aortitis; Atherosclerosis; Brachiocephalic Trunk; Collagen; Disease Models, Animal; Disease Progression; Inflammation Mediators; Interleukin-6; Lipid Metabolism; Male; Mice, Knockout, ApoE; Minocycline; Necrosis; Plaque, Atherosclerotic; Pravastatin; Time Factors | 2020 |
Effects of Pravastatin on Type 1 Diabetic Rat Heart with or without Blood Glycemic Control.
Topics: Animals; Blood Glucose; Collagen Type I; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Disease Progression; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardium; Peptidyl-Dipeptidase A; Pravastatin; Rats; Rats, Inbred Lew; Reactive Oxygen Species | 2018 |
Clinical Inquiries. Do statins alter the risk or progression of dementia?
Topics: Adult; Aged; Aged, 80 and over; Cognition; Dementia; Disease Progression; Female; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Simvastatin; United States; United States Food and Drug Administration | 2018 |
Statins for treating stable angina: can statins improve the plaque morphology and angina?
Topics: Angina Pectoris; Angina, Stable; Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pravastatin; Pyrroles; Ultrasonography, Interventional | 2013 |
Impact of HMG-CoA reductase inhibitors on the incidence of polyomavirus-associated nephropathy in renal transplant recipients with human BK polyomavirus viremia.
Topics: Adult; Aged; BK Virus; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kidney Diseases; Kidney Transplantation; Male; Middle Aged; Polyomavirus Infections; Postoperative Complications; Pravastatin; Treatment Outcome; Tumor Virus Infections; Viremia | 2015 |
Pravastatin has no advantage in small-cell lung cancer.
Topics: Antineoplastic Agents; Clinical Decision-Making; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Humans; Lung Neoplasms; Patient Selection; Pravastatin; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Time Factors; Treatment Outcome | 2017 |
The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Statins for slowing kidney disease progression: an as yet unproven indication.
Topics: Chronic Disease; Disease Progression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pravastatin; Treatment Outcome | 2008 |
Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology.
Topics: Aged; Aorta; Aortic Aneurysm, Abdominal; Atorvastatin; Biomarkers; Cathepsin A; Cathepsin B; Chi-Square Distribution; Cohort Studies; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Interleukins; Lymphotoxin-alpha; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Netherlands; Pravastatin; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Tumor Necrosis Factor-alpha; Vascular Surgical Procedures | 2010 |
Mannose binding lectin 2 haplotypes do not affect the progression of coronary atherosclerosis in men with proven coronary artery disease treated with pravastatin.
Topics: Coronary Angiography; Coronary Artery Disease; Disease Progression; Genotype; Haplotypes; Humans; Male; Mannose-Binding Lectin; Middle Aged; Polymorphism, Genetic; Pravastatin | 2011 |
HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Topics: Aged; Area Under Curve; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Plaque, Atherosclerotic; Pravastatin; Prospective Studies; ROC Curve; Sensitivity and Specificity; Treatment Outcome | 2011 |
Low-density lipoprotein lowering and atherosclerosis progression: does more mean less?
Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Pravastatin; Pyrroles; Ultrasonography | 2002 |
Clash of the statins? A trial pitting two popular statins against each other helps answer a far more important question: how low should cholesterol go?
Topics: Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure.
Topics: Animals; Anticholesteremic Agents; Atrial Natriuretic Factor; Collagen; Disease Progression; Fibronectins; Glutathione; Heart Failure; Hypertrophy, Left Ventricular; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Models, Animal; Myocardium; Myosin Heavy Chains; NADPH Oxidases; Natriuretic Peptide, Brain; Oxidative Stress; Pravastatin; Rats; Rats, Inbred Dahl; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sodium Chloride, Dietary; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2006 |
The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
Topics: Acetylcholine; Animals; Apoptosis; Blood Pressure; Blotting, Western; Body Weight; Caspase 3; Disease Progression; Endothelial Cells; Heart Function Tests; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Immunohistochemistry; In Situ Nick-End Labeling; Lung; Male; Monocrotaline; Nitric Oxide Synthase Type III; Nitroprusside; Poisons; Pravastatin; Pulmonary Artery; Rats; Rats, Wistar; Survival; Vasodilator Agents | 2006 |
Polymorphism of the cholesteryl ester transfer protein gene.
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Disease Progression; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Polymorphism, Genetic; Pravastatin | 1998 |
Polymorphism of the cholesteryl ester transfer protein gene.
Topics: Alcohol Drinking; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diet; Disease Progression; Genotype; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin | 1998 |
Effects of chronic combined treatment with captopril and pravastatin on the progression of insulin resistance and cardiovascular alterations in an experimental model of obesity in dogs.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Captopril; Cardiovascular Diseases; Cholesterol; Coronary Vessels; Disease Models, Animal; Disease Progression; Dogs; Drug Therapy, Combination; Heart; Insulin; Insulin Resistance; Linear Models; Male; Multivariate Analysis; Myocardium; Obesity; Pravastatin; Triglycerides | 1998 |
Double filtration plasmapheresis maintains normal adhesion molecule levels.
Topics: Anticholesteremic Agents; Arteriosclerosis; Biomarkers; Cell Adhesion Molecules; Cholesterol; Disease Progression; Endothelium, Vascular; Filtration; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intercellular Adhesion Molecule-1; Myocardial Ischemia; Peripheral Vascular Diseases; Plasmapheresis; Pravastatin; Thrombomodulin; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 1998 |
Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cholesterol, Dietary; Disease Progression; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Hemolytic Plaque Technique; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Peroxidation; Lipid Peroxides; Lipids; Macrophages; Male; Muscle, Smooth, Vascular; Pravastatin; Rabbits; Thiobarbituric Acid Reactive Substances | 2000 |
Diabetic retinopathy and serum lipids.
Topics: Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol; Diabetic Retinopathy; Disease Progression; Exudates and Transudates; Female; Humans; Hyperlipidemias; Laser Coagulation; Lipoproteins, LDL; Pravastatin; Triglycerides | 2000 |
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Echocardiography; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Multivariate Analysis; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; Vascular Patency | 2001 |
Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Cholesterol; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Disease Progression; Humans; Hypoglycemic Agents; Insulin; Markov Chains; Middle Aged; Pravastatin; Quality-Adjusted Life Years; Sulfonylurea Compounds; United States | 2002 |